Intellia Therapeutics — November 12, 2026 Earnings Summary

Intellia Therapeutics has submitted a Biologics License Application for lonvo-z, an investigational one-time in vivo CRISPR gene editing therapy for hereditary angioedema (HAE), with a PDUFA goal date of March 10, 2027. Phase 3 HAELO trial data demonstrated a 62% reduction in mean attack rates and an 87% reduction in attack-free weeks compared to placebo, with benefits sustained for up to four years in long-term follow-up. The treatment permanently inactivates the KLKB1 gene to stop excess kallikrein production, offering a potential cure that eliminates the need for chronic long-term prophylaxis and significantly reduces the disease burden for patients.